Get the Stockscreener App
0.9131
8.19%
0.0691
Cytosorbents Corp stock is traded at $0.9131, with a volume of 346.32K.
It is up +8.19% in the last 24 hours and down -8.69% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$0.844
Open:
$0.919
24h Volume:
346.32K
Relative Volume:
1.98
Market Cap:
$57.31M
Revenue:
$33.79M
Net Income/Loss:
$-18.67M
P/E Ratio:
-2.5491
EPS:
-0.3582
Net Cash Flow:
$-19.17M
1W Performance:
-21.28%
1M Performance:
-8.69%
6M Performance:
-20.60%
1Y Performance:
-12.20%
1-Day Range:
$0.88
$0.99
1-Week Range:
$0.8267
$1.1882
52-Week Range:
$0.7101
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.9131 | 69.04M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
CytoSorbents provides update of its appeal with FDA regarding DrugSorb-ATR - TipRanks
What technical models suggest about Cytosorbents Corporation’s comebackJuly 2025 Big Picture & Step-by-Step Swing Trade Plans - Newser
FDA upholds denial of CytoSorbents’ DrugSorb-ATR device, offers path forward - Investing.com
FDA Opens New Path Forward: CytoSorbents' Breakthrough Device for Critical Heart Surgery Patients Shows Safety - Stock Titan
Analyzing net buyer seller activity in Cytosorbents Corporation2025 Performance Recap & Community Verified Watchlist Alerts - Newser
How to integrate Cytosorbents Corporation into portfolio analysis tools2025 Dividend Review & Verified Entry Point Signals - Newser
How to read the order book for Cytosorbents CorporationJuly 2025 Momentum & Low Drawdown Momentum Ideas - Newser
Will Cytosorbents Corporation price bounce be sustainable2025 Major Catalysts & Growth Focused Entry Reports - Newser
Cytosorbents Corp Q2 2025 Earnings Call Highlights - MSN
Sector ETF performance correlation with Cytosorbents CorporationMarket Trend Summary & Detailed Earnings Play Alerts - Newser
Market reaction to Cytosorbents Corporation’s recent newsTrade Signal Summary & Entry Point Strategy Guides - Newser
Pattern recognition hints at Cytosorbents Corporation upsideJuly 2025 Review & Low Drawdown Trading Strategies - Newser
What recovery options are there for Cytosorbents Corporation2025 Trading Recap & Growth Focused Entry Reports - Newser
Is this a good reentry point in Cytosorbents CorporationTrade Risk Assessment & Daily Entry Point Trade Alerts - Newser
Cytosorbents FY2025 EPS Estimate Boosted by Zacks Small Cap - Defense World
Is now a turning point for Cytosorbents Corporation2025 Bull vs Bear & Free Long-Term Investment Growth Plans - Newser
Will Cytosorbents Corporation continue its uptrendWeekly Trade Analysis & Reliable Entry Point Alerts - Newser
Why Cytosorbents Corporation stock attracts strong analyst attentionJuly 2025 Market Mood & Advanced Technical Analysis Signals - Newser
Is Cytosorbents Corporation reversing from oversold territory2025 Risk Factors & Long-Term Safe Investment Plans - Newser
Technical signs of recovery in Cytosorbents CorporationCPI Data & Long-Term Growth Plans - Newser
How sentiment analysis helps forecast Cytosorbents CorporationWeekly Trend Recap & Free Technical Pattern Based Buy Signals - Newser
Momentum divergence signals in Cytosorbents Corporation chartTrade Performance Summary & Stepwise Entry/Exit Trade Alerts - Newser
How Efficient Is Cytosorbents Corporation at Controlling Operating CostsJuly 2025 Snapshot & AI Forecasted Stock Moves - Newser
Volume spikes in Cytosorbents Corporation stock – what they mean2025 Historical Comparison & Reliable Price Breakout Signals - Newser
Tools to assess Cytosorbents Corporation’s risk profileTreasury Yields & AI Enhanced Market Trend Forecasts - Newser
How to forecast Cytosorbents Corporation trends using time seriesEarnings Recap Report & Low Drawdown Investment Ideas - Newser
Published on: 2025-08-12 20:31:12 - Newser
Cytosorbents Corporation (NASDAQ:CTSO) Q2 2025 Earnings Call Transcript - Insider Monkey
Exit strategy if you’re trapped in Cytosorbents CorporationJuly 2025 Market Mood & Real-Time Chart Pattern Alerts - Newser
Can volume confirm reversal in Cytosorbents CorporationExit Strategy Guide With Risk Control Plan - Newser
What institutions are buying Cytosorbents Corporation stock now5-Year Price Trend Summary and Analysis - Newser
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytosorbents Corp Stock (CTSO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MARIANI PETER J | Chief Financial Officer |
Dec 13 '24 |
Buy |
0.96 |
20,000 |
19,294 |
401,363 |
| MARIANI PETER J | Chief Financial Officer |
Dec 12 '24 |
Buy |
0.89 |
20,000 |
17,872 |
381,363 |
| MARIANI PETER J | Chief Financial Officer |
Dec 11 '24 |
Buy |
0.89 |
11,363 |
10,103 |
361,363 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):